The benefit of treating a previously unstoppable genetic cause of blindness is immeasurable.
Janssen is committed to translating our understanding of the underlying biology of retinal diseases to develop needed therapies that restore and preserve vision.
Our Expansive Legacy
At Janssen, patient needs set the priorities. We have a legacy of entering spaces with innovations that transform lives. From young children to those young at heart, our commitment to eye diseases is no exception. We believe Janssen’s deep experience in pharmaceuticals and Johnson & Johnson’s broad ophthalmic footprint makes us well positioned to deliver on our mission: to restore and preserve vision.
Impact of Retinal Diseases and Our Areas of Focus
Retinal diseases are devastating and threaten the eyesight of millions worldwide.1,2,3 Current treatments, when they exist, have therapeutic limitations or require regimens that are difficult to maintain.4,5 Our clinical-stage retinal portfolio includes leading product candidates for inherited retinal diseases X-linked retinitis pigmentosa (XLRP) and achromatopsia, as well as therapies for more common eye diseases, including age-related macular degeneration, diabetic retinopathy and diabetic macular edema.
There are currently no approved treatments for XLRP and achromatopsia.6 For those suffering from diabetic retinopathy, diabetic macular edema and wet age-related macular degeneration, standard-of-care treatments are invasive and do not provide the optimal patient experience.4,5
Pioneering Science for a Better Future
We are committed to making a difference by discovering and developing transformational therapies that have an unequivocal advantage over standard of care and seeking earlier interventions in disease management.
Leveraging our expertise in immunology, vascular disease, neuroscience and gene and nucleic acid therapies, we are collaborating with leading research communities to uncover the pathology of retinal diseases, identify new targets for therapy and bring life-changing treatments to people in need.
1 Who.int. 2020. Vision Impairment and Blindness.. Accessed September 25, 2020.
2 Retina International's IRD Toolkit. 2020. Incidence and Prevalence. September 25, 2020.
3 Bourne RRA, Flaxman SR, Braithwaite T, et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(9):e888-e897.
4 American Academy of Ophthalmology. Guidelines on Diabetic Eye Care.. Accessed September 25, 2020.
5 American Academy of Ophthalmology. How is AMD Diagnosed and Treated?. Accessed September 25, 2020.
6 Wang DY, Chan WM, Tam PO, et al. Gene mutations in retinitis pigmentosa and their clinical implications. Clin Chim Acta. 2005;351(1-2):5-16.